Misshapen and bloated mitochondria in the lungs may be the reason why so many elderly develop idiopathic pulmonary fibrosis (IPF), according to a study conducted at the University of Pittsburgh School of Medicine. The research, which will be featured on the cover of the February issue of the…

Thanks to a partnership with IntelGenx Corp (IGXT), Pacific Therapeutics Ltd. is combining two approved drugs to create a once per day tablet to treat pulmonary fibrosis and other diseases that result from excess scarring. Pacific Therapeutics is a clinical stage Specialty Pharmaceutical Company that reformulates and reappropriates FDA approved drugs…

The Pulmonary Hypertension Association (PHA), the country’s leading non-profit organization for pulmonary hypertension (PH), maintains a daily blog on its website called PH Daily Beat, which provides those with PH helpful tips for living with the disease. Recently, the PHA put together…

The Pulmonary Hypertension Association (PHA), the country’s lead non-profit organization for pulmonary hypertension (PH), has just accredited the Adult Pulmonary Hypertension Program at Stanford Medicine as a comprehensive care center. This recognition and endorsement from the PHA makes the Stanford program one of…

A new collaboration between Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) was announced today. The new collaboration aims to develop new small molecule anti-fibrotic therapies and includes an agreement that enables Bristol-Myers Squibb to develop, produce and commercialize the preclinical compounds that can result from this…

Initial results are now available from a national registry that has been established in Russia to track individuals with pulmonary hypertension (PH), including chronic thromboembolic pulmonary hypertension (CTEPH). The research was published in Russian in the journal Terapevticheskii Arkhiv (translated to Therapeutic Archive). PH is a serious disease involving high blood…

United Therapeutics Corporation has signed an agreement with DEKA Research & Development Corp., to continue the development of a breakthrough technology for the subcutaneous delivery of the Remodulin (treprostinil) Injection. The device is expected to offer a potential treatment option for patients who suffer from pulmonary arterial hypertension (PAH) and…